My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Epizyme (EPZM)
NASDAQ:EPZM
EPZM nasdaq
United States
Epizyme

Epizyme Stock Analysis & Ratings

Epizyme Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Epizyme stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

EPZM

EPZM Stock Stats

Previous Close$4.5
Open$0
Bid4.37 x 500
Ask4.5 x 200
Today’s Range$0 - $0
52-Week Range$4.28 - $14.30
VolumeN/A
Average Volume1.02M
Market Cap$460.12M
Beta1.18
P/E Ratio-1.8
EPS-2.52
Earnings DateNov 03, 2021

Company Description

Epizyme

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Grant C. Bogle
Employees
304
ISIN
US29428V1044
Address
400 Technology Square, Cambridge, MA, 02139, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

EPZM FAQ

What was Epizyme’s price range in the past 12 months?
Epizyme lowest stock price was $4.28 and its highest was $14.30 in the past 12 months.
    What is Epizyme’s market cap?
    Epizyme’s market cap is $460.12M.
      What is Epizyme’s price target?
      The average price target for Epizyme is $11.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $5.00. The average price target represents 155.56% Increase from the current price of $4.5.
        What do analysts say about Epizyme?
        Epizyme’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Epizyme’s upcoming earnings report date?
          Epizyme’s upcoming earnings report date is Nov 03, 2021 which is in 13 days.
            How were Epizyme’s earnings last quarter?
            Epizyme released its earnings results on Aug 09, 2021. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.617 by -$0.013.
              Is Epizyme overvalued?
              According to Wall Street analysts Epizyme’s price is currently Undervalued.
                Does Epizyme pay dividends?
                Epizyme does not currently pay dividends.
                What is Epizyme’s EPS estimate?
                Epizyme’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Epizyme have?
                Epizyme has 102,250,000 shares outstanding.
                  What happened to Epizyme’s price movement after its last earnings report?
                  Epizyme reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.617. Following the earnings report the stock price went down -14.992%.
                    Which hedge fund is a major shareholder of Epizyme?
                    Among the largest hedge funds holding Epizyme’s share is PRIMECAP Management Co. It holds Epizyme’s shares valued at 127M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis